Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Adv Ther
; 36(10): 2600-2617, 2019 10.
Article
in En
| MEDLINE
| ID: mdl-31432460
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Antibodies, Monoclonal, Humanized
/
B7-H1 Antigen
/
Programmed Cell Death 1 Receptor
/
Antineoplastic Agents, Immunological
/
Lung Neoplasms
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Adv Ther
Journal subject:
TERAPEUTICA
Year:
2019
Document type:
Article
Affiliation country:
Italy
Country of publication:
United States